

9660 01 NOV 14 P1 21

November 13, 2001

Dockets Management Branch
HFA-305
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20857

**RE: Comments on Docket No. 01D-0221
Draft Guidance for Industry on Biological Product Deviation Reporting for
Licensed Manufacturers of Biological Products Other than Blood and Blood
Components**

Dear Sir or Madam:

Wyeth-Ayerst Laboratories, a Division of American Home Products Corporation, hereby submits comments to Docket No. 01D-0221, pertaining to the Draft Guidance for Industry on "Biological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other than Blood and Blood Components".

Wyeth-Ayerst is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular disease therapies, central nervous system drugs, anti-inflammatory agents, anti-infective agents, vaccines, and biopharmaceuticals. American Home Products Corporation is one of the world's leading research-based pharmaceutical and healthcare products companies, and is a leading developer, manufacturer, and marketer of prescription drugs and over-the-counter medications.

We would like to propose a clarification to one aspect of the draft guidance. We note that page 3 (second paragraph) states that, "Some common manufacturing steps performed under contract include testing, filling, storage and distribution". The guidance further indicates that if the manufacturer contracts out any of these steps, the product remains under the manufacturer's control. This wording might be interpreted to mean that the manufacturer is responsible for reporting a deviation that occurs during any stage of distribution of the product.


We believe that clarification is needed to clearly indicate that the manufacturer must only report a deviation that occurs during distribution while the product is still under the manufacturer's control. This point is clearly illustrated in the example provided at the top of page 4 of the draft guidance (example no. 2). Nevertheless, it would help to avoid misinterpretation if the text on page 3 pertaining to contract manufacturing is revised to clarify that downstream distribution by wholesalers, third party distributors, pharmacy chains, etc are outside of the manufacturer's control.

01D-0221

C1

Wyeth-Ayerst appreciates the opportunity to provide this constructive input to the draft guidance. This letter is submitted in duplicate. Please contact the undersigned at (484) 865-3794 if there are any questions regarding the submitted comments.

Sincerely,

A handwritten signature in black ink, appearing to read "Roy J. Baranello, Jr.", written in a cursive style.

Roy J. Baranello, Jr.
Assistant Vice President
Worldwide Regulatory Affairs

Red EXX USA Air Mail Express

827984446969

0200

FedEx Retrieval Copy

1 From

Date 11/13/01

Sender's FedEx Account Number 2617-5937-3

Sender's Name Roy J. BARNETT 481 665-3994

Phone

Company MYCITH PHARMACEUTICALS

Address 500 ARCOLA RD

City COLLEGEVILLE

State PA

ZIP 17926

2 Your Internal Billing Reference

3 To

Recipient Name

Dockets Management Branch

Company

HFA-305

Food and Drug Administration

Address

5630 Fishers Lane, Room 1061

City

Rockville, MD 20857



4a Express Package Services Packages up to 150 lbs. (even, commitment may be later in some areas)

1 FedEx Priority Overnight FedEx Standard Overnight 6 FedEx First Overnight (even, commitment may be later in some areas)

20 FedEx Express Saver NEW! FedEx Extra Hours (even, commitment may be later in some areas)

4b Express Freight Service Packages over 150 lbs. (even, commitment may be later in some areas)

8 FedEx 1Day Freight FedEx 2Day Freight FedEx 3Day Freight

5 Packaging FedEx Envelope* FedEx Pak* Other Pkg. (Declared value limit \$500)

6 Special Handling SUNDAY Delivery HOLD Weekday HOLD Saturday at FedEx Location HOLD Saturday at FedEx Location (Available only for FedEx Priority Overnight and FedEx 2Day. Not available with FedEx First Overnight.)

7 Payment Bill to: Recipient Third Party Credit Card Cash/Check Other Recip. (Enter FedEx Acct. No. or Credit Card No. below)

8 Release Signature (Sign to accept delivery without obtaining signature) *Debra Johnson*

By signing you authorize us to deliver the shipment without obtaining a signature and agree to indemnify and hold us harmless from any resulting claims.

404

Mr. Dan T. O'Connell #155974 • 12500 WISCONSIN AVE. • GPO # 301